Share on StockTwits

Insys Therapeutics (NASDAQ:INSY) Director Theodore H. Stanley bought 3,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were purchased at an average price of $33.93 per share, for a total transaction of $101,790.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $33,930. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Insys Therapeutics (NASDAQ:INSY) traded up 6.43% during mid-day trading on Friday, hitting $34.75. The stock had a trading volume of 604,476 shares. Insys Therapeutics has a 52 week low of $16.20 and a 52 week high of $57.9133. The stock has a 50-day moving average of $28.49 and a 200-day moving average of $34.69. The company has a market cap of $1.199 billion and a price-to-earnings ratio of 22.67.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Tuesday, August 12th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.28. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $52.77 million. Analysts expect that Insys Therapeutics will post $1.08 EPS for the current fiscal year.

Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.